시장보고서
상품코드
1429904

세계의 파마코게노믹스 시장 보고서(2024년)

Pharmacogenomics Global Market Report 2024

발행일: | 리서치사: The Business Research Company | 페이지 정보: 영문 200 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    


■ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

파마코게노믹스 시장 규모는 향후 몇 년 동안 빠르게 성장할 것으로 예상됩니다. 2028년에는 10.5%의 연평균 복합 성장률(CAGR)로 134억 8,000만 달러 규모로 성장할 것으로 예상됩니다. 예측 기간 동안 예상되는 성장은 고령화 증가, 만성질환 증가, 총 인구 증가, 암 치료 수요 증가 등의 요인에 기인하는 것으로 보입니다. 예측 기간 동안 예상되는 주요 동향으로는 고급 치료의 심층 분석을 위한 유전체 편집 솔루션 출시, 유전자 데이터 분석을 위한 유전체학에 인공지능(AI) 통합에 대한 관심, 메타게놈학의 지속적인 발전, 시장 기업 간의 전략적 파트너십과 협업, 유전자 발현과 기능에 미치는 영향을 연구하기 위한 3차원(3D) 유전체학의 도입, 감염성 질환과 유전자 편집에 초점을 맞춘 신제품 혁신, 정보에 입각한 의사결정을 위한 향정신성 약물 유전체학 검사 개발 등이 포함됩니다.

정밀의료에 대한 수요 증가로 인해 파마코게노믹스 시장 확대가 가속화되고 있습니다. 특정 환자군에 대한 맞춤형 치료에 초점을 맞춘 헬스케어 모델인 정밀의료는 특히 종양학 등 첨단 분야에서 주목을 받고 있습니다. 그 적용 범위는 말기 질환을 넘어 희귀 유전질환까지 확대되고 있습니다. 정밀의료는 유전정보와 환경정보를 통합해 특정 질병과 반응에 맞는 치료법을 제공하는 것을 목표로 합니다. 2022년 3월 린치핀세오(Lynchpinseo)의 기사에 따르면, 향후 5년 동안 주요 제약사의 정밀의료 투자가 1/3 증가할 것으로 예상했습니다. 3,000만 명의 제2형 당뇨병 환자가 진단 및 치료를 받고 있는 미국에서는 정밀의료가 개인화된 치료법을 제공함으로써 현재의 진료 방식을 재구성하고 있습니다. 정밀의료에 대한 수요 증가는 파마코게노믹스 시장을 이끄는 주요 원동력이 되고 있습니다.

파마코게노믹스 시장은 만성질환의 유병률 증가로 인해 성장할 것으로 예상됩니다. 만성질환은 장기간 지속되며 전 세계적으로 심각한 건강 문제를 야기합니다. 파마코게노믹스는 약물 반응에 영향을 미치는 개인의 유전적 차이를 고려한 맞춤형 치료 접근법을 제공합니다. 세계보건기구(WHO)의 2023년 9월 보고서에 따르면, 전 세계 연간 사망자 4,100만 명 중 74%가 비감염성 질환(NCD) 또는 만성질환으로 인한 사망자입니다. 심혈관 질환, 암, 만성 호흡기 질환, 당뇨병이 이러한 부담에 크게 기여하고 있습니다. 만성질환의 증가 추세는 파마코게노믹스 시장을 이끄는 주요 요인입니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 거시경제 시나리오

  • 고인플레이션이 시장에 미치는 영향
  • 우크라이나·러시아 전쟁이 시장에 미치는 영향
  • COVID-19에 의한 시장에 대한 영향

제5장 세계 시장 규모와 성장

  • 세계의 시장 성장 촉진요인과 억제요인
    • 시장 성장 촉진요인
    • 시장 성장 억제요인
  • 세계의 시장 규모 실적과 성장, 2018-2023년
  • 세계의 시장 규모 예측과 성장, 2023-2028년, 2033년

제6장 시장 세분화

  • 세계의 파마코게노믹스 시장, 기술별 세분화, 실적 및 예측, 2018-2023년, 2023-2028년, 2033년
  • 차세대 시퀀싱
  • 중합효소 연쇄 반응
  • 겔 전기영동
  • 질량분석법
  • 마이크로어레이
  • 기타 기술
  • 세계의 파마코게노믹스 시장, 용도별 세분화, 실적 및 예측, 2018-2023년, 2023-2028년, 2033년
  • 신경내과
  • Drug Discovery
  • 종양학
  • 심장병학
  • 통증 관리
  • 기타 용도
  • 세계의 파마코게노믹스 시장, 최종사용자별 세분화, 실적 및 예측, 2018-2023년, 2023-2028년, 2033년
  • 병원과 진료소
  • 연구기관
  • 학술기관

제7장 지역 및 국가 분석

  • 세계의 파마코게노믹스 시장, 지역별, 실적 및 예측, 2018-2023년, 2023-2028년, 2033년
  • 세계의 파마코게노믹스 시장, 국가별, 실적 및 예측, 2018-2023년, 2023-2028년, 2033년

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 상황과 기업 개요

  • 파마코게노믹스 시장 경쟁 상황
  • 파마코게노믹스 시장 기업 개요
    • Illumina Inc
    • Eurofins Scientific
    • Myriad Genetics Inc
    • PerkinElmer Inc
    • Centogene NV

제31장 기타 주요 및 혁신적인 기업

  • Invitae Corporation
  • Genomind
  • Pacific Biosciences of California Inc
  • Oneome LLC
  • Admera Health
  • MapMyGenome
  • Positive Bioscience
  • Xcode Life Sciences
  • Xcelris Labs
  • Takeda Pharmaceutical Company Limited
  • Garvan Institute of Medical Research
  • 3D Medicines Inc
  • Berry Genomics
  • BGI
  • GenomiCare Biotechnology

제32장 경쟁 벤치마킹

제33장 경쟁 대시보드

제34장 주요 인수합병

제35장 향후 전망과 가능성 분석

제36장 부록

ksm 24.03.27

Pharmacogenomics is a research field that explores how a patient's genes influence their response to medications. Its ultimate goal is to assist doctors in selecting the most appropriate drugs and doses tailored to each individual. Pharmacogenomics is instrumental in developing personalized drugs to address various health conditions, including cardiovascular disease, Alzheimer's disease, cancer, and asthma. The term 'pharmacogenomics marker' refers to a precise medical treatment approach for individuals or specific groups.

Key technologies employed in the pharmacogenomics market include next-generation sequencing (NGS), polymerase chain reaction, gel electrophoresis, mass spectrometry, microarray, and others. NGS, a massively parallel sequencing technology, offers ultra-high throughput, scalability, and speed, enabling the determination of nucleotide order in entire genomes or specific DNA/RNA regions. Pharmacogenomics applications span neurological diseases, infectious diseases, oncology, cardiovascular diseases, pain management, and various other areas. End-users encompass hospitals and clinics, research institutions, academic institutes, and others.

The pharmacogenomics market research report is one of a series of new reports from The Business Research Company that provides pharmacogenomics market statistics, including pharmacogenomics industry global market size, regional shares, competitors with a pharmacogenomics market share, detailed pharmacogenomics market segments, market trends and opportunities, and any further data you may need to thrive in the pharmacogenomics industry. This pharmacogenomics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The pharmacogenomics market size has grown rapidly in recent years. It will grow from $8.14 billion in 2023 to $9.04 billion in 2024 at a compound annual growth rate (CAGR) of 11.1%. The expansion observed in the historical period can be attributed to robust economic growth in emerging markets, a growing emphasis on personalized medicine, the development of advanced healthcare infrastructure, and an increase in healthcare expenditure.

The pharmacogenomics market size is expected to see rapid growth in the next few years. It will grow to $13.48 billion in 2028 at a compound annual growth rate (CAGR) of 10.5%. The anticipated growth in the forecast period can be attributed to factors such as the increasing aging population, a rise in chronic diseases, a growing overall population, and an increasing demand for cancer treatment. Key trends expected in the forecast period include the launch of genome editing solutions for a more in-depth analysis of advanced therapies, a focus on integrating artificial intelligence (AI) in genomics for the analysis of genetic data, continuous advancements in metagenomics, strategic partnerships and collaborations among market players, the introduction of three-dimensional (3D) genomics to study influences on gene expression and function, new product innovations with a focus on infectious diseases and gene editing, and the development of psychotropic pharmacogenomics tests for informed decision-making.

The growing demand for precision medicine is fueling the expansion of the pharmacogenomics market. Precision medicine, a healthcare model focused on personalized treatment tailored to specific patient subsets, is gaining traction, especially in advanced areas such as oncology. Its applications extend beyond late-stage diseases to encompass rare and genetic conditions. Precision medicine aims to integrate genetic and environmental information to tailor treatments for specific diseases and responses. A Linchpinseo article from March 2022 indicates a 1/3 increase in precision medicine investment by leading pharmaceutical companies over the next five years. In the USA, where 30 million people with type 2 diabetes are diagnosed and treated, precision medicine offers individualized treatment, reshaping current practices. The rising demand for precision medicine is a key driver propelling the pharmacogenomics market.

The pharmacogenomics market is expected to experience growth due to the increasing prevalence of chronic diseases. Chronic diseases, persistent over an extended period, pose a significant global health challenge. Pharmacogenomics provides a personalized treatment approach, considering individual genetic variations influencing drug responses. According to the World Health Organization's September 2023 report, non-communicable diseases (NCDs) or chronic diseases account for 74% of the 41 million annual deaths worldwide. Cardiovascular diseases, cancer, chronic respiratory diseases, and diabetes contribute significantly to this burden. The upward trend in chronic diseases is a major factor propelling the pharmacogenomics market.

A noteworthy trend in the pharmacogenomics market is technological advancement. Medicine manufacturers are actively pursuing various approaches to pharmacogenomics analysis, aiming to offer cost-effective solutions for screening known polymorphisms and discovering novel variants. In May 2021, Integrated Prescription Management (IPM), a U.S.-based pharmacy benefits management (PBM) company, collaborated with Myriad Genetics Inc. to launch the GeneSight test. This pharmacogenomics testing solution targets patients dealing with depression or anxiety, showcasing technological advancements in precision medicine.

Companies in the pharmacogenomics market are concentrating on the development of innovative solutions for infectious disease diagnosis and gene editing to fortify their market standing. For instance, in March 2022, Thermo Fisher Scientific Inc., a U.S.-based supplier of analytical instruments and life sciences solutions, introduced the latest generation of its SeqStudio Flex Series Genetic Analyzer. This innovative tool, leveraging Capillary Electrophoresis (CE) technology, enhances research in infectious disease diagnosis and gene editing. The SeqStudio Flex Genetic Analyzer, available in 8- and 24-capillary configurations, delivers high-quality data and reliable performance across various applications.

In June 2023, Genomenon, a U.S.-based genomics intelligence company, acquired Boston Genetics for an undisclosed amount. This strategic acquisition combines Genomenon's AI-powered genomic platform with Boston Genetics' genetic scientists to comprehensively curate the human genome. The acquisition strengthens clinical diagnostic and pharmaceutical drug development programs by providing valuable insights into the genomic drivers of genetic diseases and oncology. Additionally, it establishes a genomics data service arm for Genomenon, offering cost-effective variant curation team extensions for genetic testing labs, expediting turnaround times. Boston Genetics, a genomics interpretation and curation company based in the U.S., is part of this acquisition.

Major companies operating in the pharmacogenomics market report are Illumina Inc., Eurofins Scientific, Myriad Genetics Inc., PerkinElmer Inc., Centogene N.V, Invitae Corporation, Genomind, Pacific Biosciences of California Inc., Oneome LLC, Admera Health, MapMyGenome, Positive Bioscience, Xcode Life Sciences, Xcelris Labs, Takeda Pharmaceutical Company Limited, Garvan Institute of Medical Research, 3D Medicines Inc., Berry Genomics, BGI, GenomiCare Biotechnology, Biotecan Pharmaceuticals, Bayer AG, GlaxoSmithKline plc (GSK), F Hoffmann-La Roche AG, Merck KGaA, Future Science Group, QIAGEN N.V, Institute of Biomedical Chemistry, Centro de Genoma e Biologia de Sistemas (CGBS), Dasa Group, Datar Cancer Genetics Limited, MedGenome Labs, AnorMed, 23andMe, Myriad Genetics, Color Genomics, Pathway Genomics, Laboratorio Richet, Laboratorio Exame, Genomika Diagnosticos, Gulf Pharmaceutical Industries JULPHA, Neopharm, NewBridge Pharmaceuticals Limited, EIPICO (Egyptian International Pharmaceutical Industries Company), Aspen Pharmacare Holdings Limited, Pharma-Q (Pty) Ltd

North America was the largest region in the pharmacogenomics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pharmacogenomics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the pharmacogenomics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The pharmacogenomics market includes revenues earned by entities by PennCNV,QuantiSNP, GenoCN and Nexus.The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Pharmacogenomics Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on pharmacogenomics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for pharmacogenomics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The pharmacogenomics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Technology: Next Generation Sequencing; Polymerase Chain Reaction; Gel Electrophoresis; Mass Spectrometry; Microarray; Other Technologies
  • 2) By Application: Neurological Diseases; Infectious Diseases; Oncology; Cardiovascular Diseases; Pain Management; Other Applications
  • 3) By End User: Hospitals and Clinics; Research Institutions; Academic Institutes; Other End Users
  • Companies Mentioned: Illumina Inc; Eurofins Scientific; Myriad Genetics Inc; PerkinElmer Inc; Centogene N.V
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Pharmacogenomics Market Characteristics

3. Pharmacogenomics Market Trends And Strategies

4. Pharmacogenomics Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Pharmacogenomics Market Size and Growth

  • 5.1. Global Pharmacogenomics Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Pharmacogenomics Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Pharmacogenomics Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Pharmacogenomics Market Segmentation

  • 6.1. Global Pharmacogenomics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Next Generation Sequencing
  • Polymerase Chain Reaction
  • Gel Electrophoresis
  • Mass Spectrometry
  • Microarray
  • Other Technologies
  • 6.2. Global Pharmacogenomics Market, Segmentation By Applications , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Neurology
  • Drug Discovery
  • Oncology
  • Cardiology
  • Pain Management
  • Other Applications
  • 6.3. Global Pharmacogenomics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals And Clinics
  • Research Institutions
  • Academic Institutes

7. Pharmacogenomics Market Regional And Country Analysis

  • 7.1. Global Pharmacogenomics Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Pharmacogenomics Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Pharmacogenomics Market

  • 8.1. Asia-Pacific Pharmacogenomics Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Pharmacogenomics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Pharmacogenomics Market, Segmentation By Applications , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Pharmacogenomics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Pharmacogenomics Market

  • 9.1. China Pharmacogenomics Market Overview
  • 9.2. China Pharmacogenomics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Pharmacogenomics Market, Segmentation By Applications , Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Pharmacogenomics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Pharmacogenomics Market

  • 10.1. India Pharmacogenomics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Pharmacogenomics Market, Segmentation By Applications , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Pharmacogenomics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Pharmacogenomics Market

  • 11.1. Japan Pharmacogenomics Market Overview
  • 11.2. Japan Pharmacogenomics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Pharmacogenomics Market, Segmentation By Applications , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Pharmacogenomics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Pharmacogenomics Market

  • 12.1. Australia Pharmacogenomics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Pharmacogenomics Market, Segmentation By Applications , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Pharmacogenomics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Pharmacogenomics Market

  • 13.1. Indonesia Pharmacogenomics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Pharmacogenomics Market, Segmentation By Applications , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Pharmacogenomics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Pharmacogenomics Market

  • 14.1. South Korea Pharmacogenomics Market Overview
  • 14.2. South Korea Pharmacogenomics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Pharmacogenomics Market, Segmentation By Applications , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Pharmacogenomics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Pharmacogenomics Market

  • 15.1. Western Europe Pharmacogenomics Market Overview
  • 15.2. Western Europe Pharmacogenomics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Pharmacogenomics Market, Segmentation By Applications , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Pharmacogenomics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Pharmacogenomics Market

  • 16.1. UK Pharmacogenomics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Pharmacogenomics Market, Segmentation By Applications , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Pharmacogenomics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Pharmacogenomics Market

  • 17.1. Germany Pharmacogenomics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Pharmacogenomics Market, Segmentation By Applications , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Pharmacogenomics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Pharmacogenomics Market

  • 18.1. France Pharmacogenomics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Pharmacogenomics Market, Segmentation By Applications , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Pharmacogenomics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Pharmacogenomics Market

  • 19.1. Italy Pharmacogenomics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Pharmacogenomics Market, Segmentation By Applications , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Pharmacogenomics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Pharmacogenomics Market

  • 20.1. Spain Pharmacogenomics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Pharmacogenomics Market, Segmentation By Applications , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Pharmacogenomics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Pharmacogenomics Market

  • 21.1. Eastern Europe Pharmacogenomics Market Overview
  • 21.2. Eastern Europe Pharmacogenomics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Pharmacogenomics Market, Segmentation By Applications , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Pharmacogenomics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Pharmacogenomics Market

  • 22.1. Russia Pharmacogenomics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Pharmacogenomics Market, Segmentation By Applications , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Pharmacogenomics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Pharmacogenomics Market

  • 23.1. North America Pharmacogenomics Market Overview
  • 23.2. North America Pharmacogenomics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Pharmacogenomics Market, Segmentation By Applications , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Pharmacogenomics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Pharmacogenomics Market

  • 24.1. USA Pharmacogenomics Market Overview
  • 24.2. USA Pharmacogenomics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Pharmacogenomics Market, Segmentation By Applications , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Pharmacogenomics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Pharmacogenomics Market

  • 25.1. Canada Pharmacogenomics Market Overview
  • 25.2. Canada Pharmacogenomics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Pharmacogenomics Market, Segmentation By Applications , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Pharmacogenomics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Pharmacogenomics Market

  • 26.1. South America Pharmacogenomics Market Overview
  • 26.2. South America Pharmacogenomics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Pharmacogenomics Market, Segmentation By Applications , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Pharmacogenomics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Pharmacogenomics Market

  • 27.1. Brazil Pharmacogenomics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Pharmacogenomics Market, Segmentation By Applications , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Pharmacogenomics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Pharmacogenomics Market

  • 28.1. Middle East Pharmacogenomics Market Overview
  • 28.2. Middle East Pharmacogenomics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Pharmacogenomics Market, Segmentation By Applications , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Pharmacogenomics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Pharmacogenomics Market

  • 29.1. Africa Pharmacogenomics Market Overview
  • 29.2. Africa Pharmacogenomics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Pharmacogenomics Market, Segmentation By Applications , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Pharmacogenomics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Pharmacogenomics Market Competitive Landscape And Company Profiles

  • 30.1. Pharmacogenomics Market Competitive Landscape
  • 30.2. Pharmacogenomics Market Company Profiles
    • 30.2.1. Illumina Inc
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Eurofins Scientific
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Myriad Genetics Inc
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. PerkinElmer Inc
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Centogene N.V
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Pharmacogenomics Market Other Major And Innovative Companies

  • 31.1. Invitae Corporation
  • 31.2. Genomind
  • 31.3. Pacific Biosciences of California Inc
  • 31.4. Oneome LLC
  • 31.5. Admera Health
  • 31.6. MapMyGenome
  • 31.7. Positive Bioscience
  • 31.8. Xcode Life Sciences
  • 31.9. Xcelris Labs
  • 31.10. Takeda Pharmaceutical Company Limited
  • 31.11. Garvan Institute of Medical Research
  • 31.12. 3D Medicines Inc
  • 31.13. Berry Genomics
  • 31.14. BGI
  • 31.15. GenomiCare Biotechnology

32. Global Pharmacogenomics Market Competitive Benchmarking

33. Global Pharmacogenomics Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Pharmacogenomics Market

35. Pharmacogenomics Market Future Outlook and Potential Analysis

  • 35.1 Pharmacogenomics Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Pharmacogenomics Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Pharmacogenomics Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제